ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1154

Assessment Of Damage Using The IgG4-Related Disease Damage Index.

Eduardo Martin-Nares1 and Gabriela Hernandez-Molina2, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico

Meeting: ACR Convergence 2025

Keywords: Damage Index, IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder affecting multiple organs, often leading to irreversible damage. Standardized tools like the IgG4-RD Damage Index (DI) are crucial for understanding disease progression and phenotype-specific characteristics, but their performance remains untested in non-Chinese populations. This study aimed to assess damage in Mexican IgG4-RD patients using the IgG4-RD DI.

Methods: We conducted a retrospective study of patients with IgG4-RD who met the 2020 Revised Comprehensive Diagnostic Criteria and/or the 2019 ACR/EULAR Classification Criteria for IgG4-RD. All patients were followed for at least one year. Damage was defined as irreversible organ dysfunction or failure caused by IgG4-RD or by procedures performed for its diagnosis or treatment and persisted for at least six months. Damage was assessed using the IgG4-RD DI at the last follow-up.

Results: We included 70 patients with a mean age of 52.1 ± 15.6 years, of whom 34 (48.6%) were male. The median duration of disease (from symptom onset to last follow-up) was 77.5 months (IQR 54–133). At the last follow-up, organ damage was detected in 56 patients (80%) based on the IgG4-RD RI. The median DI score for the entire cohort was 1 (IQR 0–3), while for patients with damage it was 2 (IQR 1–3; range 1–9). Figure 1 shows the distribution of IgG4-RD DI scores. The most frequently affected organ-specific domains of the IgG4-RD DI were ‘Pancreas’ (31.4%), ‘Lung’ (15.7%), ‘Kidney’ (11.4%), ‘Retroperitoneum/mediastinum’ (8.6%), and ‘Liver/biliary tree’ (8.6%). The ‘Others’ domain was scored in 26 patients (37.1%), primarily due to partial or total organ resection related to IgG4-RD (22.8%), disease-related or treatment-related diabetes mellitus (15.7%), and damage in other organs (14.3%). Patients with the head and neck-limited phenotype had lower DI scores (p=0.05). The ‘Retroperitoneum/mediastinum’ domain was scored more frequently in the retroperitoneal/aortic phenotype (p< 0.001), while the ‘Pancreas’ domain was scored more frequently in the pancreato-biliary and Mikulicz/systemic phenotypes (p=0.001). The ‘Kidney’ domain was more commonly scored in the retroperitoneal/aortic phenotype (p=0.01), due to obstructive nephropathy. The proliferative phenotype had more commonly damage in the ‘Pancreas’ domain (p=0.01), while the fibrotic phenotype in the ‘Retroperitoneum/mediastinum’ (p< 0.001) and ‘Thyroid’ domains (p=0.02). There were no significant differences in DI scores or domain involvement between men and women.Comparing patients with and without damage (Table 1), the former group was less likely to have the head and neck-limited phenotype (20.4% vs. 56.3%, p=0.005; OR: 0.16), and more likely to have elevated IgG levels (60.9% vs. 31.3%, p=0.04; OR: 4.67).

Conclusion: Organ damage is frequent in IgG4-RD, varies by phenotype, and is most common in the pancreas. Elevated IgG levels increase damage risk, while the head and neck-limited phenotype is protective. Organ resections for diagnostic or therapeutic purposes and glucocorticoid toxicity are key contributors to cumulative damage in IgG4-RD.

Supporting image 1Figure 1. Distribution of the IgG4-RD DI scores

Supporting image 2Table 1. Characteristics of patients with damage vs. no damage.


Disclosures: E. Martin-Nares: None; G. Hernandez-Molina: None.

To cite this abstract in AMA style:

Martin-Nares E, Hernandez-Molina G. Assessment Of Damage Using The IgG4-Related Disease Damage Index. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/assessment-of-damage-using-the-igg4-related-disease-damage-index/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-damage-using-the-igg4-related-disease-damage-index/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology